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Objectives. The accurate diagnosis of chronic pulmonary
thromboembolism (CPTE) is a prerequisite for life-saving surgi-
cal interventions. To help in the differential diagnosis of CPTE
and primary pulmonary hypertension (PPH), we characterized
the configuration of the pulmonary artery pressure waveform.
Background. Because CPTE predominantly involves the proxi-
mal arteries, whereas PPH involves the peripheral arteries, we
hypothesized that patients with CPTE would have stiff or high
resistance proximal arteries, whereas those affected by PPH would
have high resistance peripheral arteries. These differences in the
primary lesions would make arterial pulsatility relative to mean
pressure larger in CPTE than in PPH.
Methods. In 34 patients with either CPTE (n 5 22) or PPH
(n 5 12) whose pulmonary systolic pressure was >250 mm Hg, we
measured pulmonary artery pressure using a fluid-filled system
that included a balloon-tipped flow-directed catheter.
Results. To quantify the magnitude of pulsatility relative to
mean pressure, we normalized pulse pressure by mean pressure,
hereinafter referred to as fractional pulse pressure (PPf). PPf was
markedly higher in CPTE than in PPH (mean [6 SD] 1.41 6 0.20
and 0.80 6 0.18, respectively, p < 0.001) and was diagnostic in
separating the two groups without overlap. Similarly, the coeffi-
cient of variation of pulmonary artery pressure also separated the
two groups without overlap (0.45 6 0.06 and 0.25 6 0.06,
respectively, p < 0.001). Fractional time to half the area under the
pressure curve separated the two groups reasonably well (0.35 6
0.02 and 0.43 6 0.03, respectively, p < 0.001).
Conclusions. The analysis of pulsatility of pulmonary artery
pressure is useful in the differential diagnosis of CPTE and PPH.
(J Am Coll Cardiol 1997;29:1311–6)
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Differential diagnosis between chronic pulmonary thromboem-
bolism (CPTE) and primary pulmonary hypertension (PPH)
remains a clinical challenge. In particular, the correct diagnosis
of CPTE is a prerequisite for life-saving surgical procedures
(1). Although various diagnostic measures differentiate the two
diseases (2–5), a differential diagnosis based on pulmonary
artery pressure waveform configuration has not been estab-
lished. Because pulmonary artery pressure is relatively easy to
measure, a differential diagnosis using arterial pressure wave-
form configuration is extremely useful in clinical settings. Thus,
the purpose of this investigation was to characterize the
configuration of the pulmonary artery pressure waveform for
differentiating CPTE from PPH.
In CPTE, thrombi obstruct the proximal arteries preferen-
tially (i.e., from the main pulmonary artery to the pulmonary
segmental arteries) (6). Hence, it is conceivable that thrombi
attached to the proximal arteries mechanically stiffen the
arterial wall and increase proximal resistance without compa-
rably increasing peripheral arterial resistance. In contrast,
PPH primarily involves peripheral arteries with a diameter
,1,000 mm. Major histologic findings include intimal thicken-
ing and fibrosis of the pulmonary arterioles, increased thick-
ness of the media of the muscular pulmonary arteries and
muscularization of the arterioles (7,8). These vascular changes,
in turn, would increase arterial peripheral resistance without
inducing comparable changes in stiffness or resistance of the
proximal arteries. Because the increases in stiffness and resis-
tance in the proximal arteries would increase pulse pressure
(9–12), whereas those in peripheral resistance increase mean
arterial pressure (9,13), we hypothesized that the pulsatility of
pulmonary artery pressure relative to mean arterial pressure
would be higher in CPTE than in PPH. The results of our study
indicated that pulsatility was indeed significantly higher in
CPTE than in PPH, indicating that pulmonary artery pressure
configuration is useful in differentiating between CPTE and
PPH.
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Methods
Study subjects. We conducted a retrospective, unblinded
study of 34 patients who were admitted to the National
Cardiovascular Center, Osaka, Japan because of symptomatic
pulmonary hypertension (New York Heart Association func-
tional classes II to IV) and who were subsequently diagnosed
as having CPTE or PPH. The entrance criteria to the study
included a pulmonary systolic pressure $50 mm Hg. CPTE was
diagnosed when thromboembolism was positively diagnosed by
means of both pulmonary angiography and radioisotope ven-
tilation–perfusion imaging in patients with a clinical history
compatible with CPTE. PPH was a diagnosis of exclusion,
made when other possible etiologies of pulmonary hyperten-
sion (i.e., secondary causes), such as mitral valve diseases,
congenital heart disease, left ventricular failure and CPTE,
were excluded. We excluded from the PPH group patients with
signs of collagen vascular disease, positive antinuclear antibod-
ies, history of drug abuse, use of diet pills or history of liver
disease. There were 22 patients with CPTE (10 men, 12
women; mean [6 SD] age 52 6 11 years, range 26 to 67) and
12 with PPH (3 men, 9 women; mean age 39 6 13 years, range
19 to 63). The duration of the disease was not significantly
different between patients with CPTE (37 6 17 months) and
those with PPH (26 6 23 months, p 5 NS). Medical therapy
for pulmonary hypertension included loop diuretic drugs (n 5
16), digoxin (n 5 14), warfarin (n 5 17), calcium channel
antagonists (n 5 4) and beraprost sodium (oral prostaglandin
I2 derivative) (n 5 12). Three of 22 patients with CPTE and 1
of 12 with PPH were taking calcium channel antagonists (p 5
NS). Eight of those with CPTE and 4 with PPH were taking
beraprost sodium (p 5 NS). The protocol was in accordance
with our Institutional Guidelines for Human Research, and
each patient provided a written statement of informed consent
for diagnostic procedures required for examination by cardiac
catheterization, which stated that the results of the examina-
tion could be used for the retrospective study.
Measurement of hemodynamic variables. We measured
hemodynamic variables in the supine position. Pulmonary
artery pressure was measured at end-expiration during a short
episode of breath-holding using a fluid-filled system that
included a balloon-tipped flow-directed catheter (7F Swan-
Ganz catheter) in the main pulmonary artery. A hard copy was
made of the pressure tracing using a chart recorder (Nihon
Koden, Surgical Monitoring System, Tokyo) at a paper speed
of 100 mm/s. The waveform of instantaneous pulmonary artery
pressure was subsequently digitized from the recorder tracing
using an optical scanner (Epson, model 8000, Tokyo) at an
effective sampling rate of 200 Hz at 12-bit resolution. We
measured cardiac output taking advantage of the oxymetric
principle of Fick. Because the clinical diagnosis was not
performed in blinded manner by the person who analyzed the
pressure tracings, there might have been some bias in the
results. However, the marked differences in the pressure
waveform between CPTE and PPH minimized the possibility
that bias would have significance.
Because CPTE predominantly involves the proximal arter-
ies, whereas PPH involves the peripheral arteries, we hypoth-
esized that patients with CPTE would have stiff or high
resistance proximal arteries, whereas those with PPH would
have high resistance peripheral arteries. These differences in
the primary lesions would make arterial pulsatility relative to
mean pressure larger in the case of CPTE than in PPH. To
quantify this accentuated pulsatility in CPTE, we developed
three indexes.
Fractional pulse pressure of pulmonary artery. As shown in
Figure 1 (left), we characterized the pulsatility as the ratio of
pulse pressure to mean pressure (i.e., fractional pulse pressure
of the pulmonary artery [PPf]). The larger the PPf, the larger
the pulsatility relative to mean pressure.
Coefficient of variation. As shown in Figure 1 (center), we
derived the coefficient of variation (CV) of pulmonary artery
pressure over a cardiac cycle. The CV represents the ratio of
the variation around the mean to the mean value of pulmonary
artery pressure waveform. In other words, CV is the square
root of the ratio of pulsatile power to static power of pulmo-
nary artery pressure. We calculated CV by taking the ratio of
Abbreviations and Acronyms
CPTE 5 chronic pulmonary thromboembolism
CV 5 coefficient of variation
PPf 5 fractional pulse pressure
PPH 5 primary pulmonary hypertension
TA1/2 5 fractional time to half the area under the pulmonary artery
pressure curve
Figure 1. Schematic representation of three different indexes of
pulsatility relative to mean pressure. Left, Fractional pulse pressure
(PPf) is the ratio of pulse pressure (PP) to mean pressure (PAm).
Middle, Coefficient of variation (CV) is the ratio of the standard
deviation of pulmonary artery pressure (PASD) to mean pressure.
Right, T1 is defined as the time at which the area under the pressure
curve over the T1 period (Area1) equals the rest of the area (Area2).
Fractional time to half the pressure area (TA1/2) is the ratio of T1 to
T1 1 T2.
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the standard deviation of pulmonary artery pressure over one
cardiac cycle to the mean pulmonary artery pressure. The
larger the CV, the larger the pulsatility for a given mean
pressure.
Fractional time to half the area under the pulmonary artery
pressure curve. As shown in Figure 1 (right), we defined the
fractional time (TA1/2) to half the area under the pulmonary
artery pressure curve over one cardiac cycle. The larger the
area under the pulmonary pressure curve in systole (i.e., larger
pulsatility [as expected of CPTE]), the shorter TA1/2 should
become. We compared the performance of these three indexes
in the differential diagnosis of CPTE and PPH.
Statistical analysis. Results are expressed as mean value 6
SD. Differences in the mean values between the two groups
were compared by an unpaired t test. A p value ,0.05 was
considered significant.
Results
Illustrated in Figure 2 are the waveforms of pulmonary
artery pressure for CPTE (left) and PPH (right). Although
peak pressures are similar in the two cases, diastolic and mean
pressures are lower for CPTE than in PPH. As a result, pulse
pressure was higher by far in CPTE than in PPH.
Illustrated in Figure 3 are the pooled data representing
pulmonary hemodynamic variables. Systolic pulmonary artery
pressure was statistically significant, being only slightly lower in
CPTE than in PPH (84 6 17 and 97 6 17 mm Hg, respectively,
p , 0.05) (Fig. 3A). Diastolic pulmonary artery pressure was
lower in CPTE than PPH (23 6 7 and 48 6 12 mm Hg,
respectively, p , 0.01) (Fig. 3B). Mean pulmonary artery
pressure was also significantly lower in CPTE than in PPH
(43 6 10 and 64 6 14 mm Hg, respectively, p , 0.01) (Fig. 3C).
Pulse pressure was significantly higher in CPTE than in PPH
(61 6 12 and 50 6 10 mm Hg, respectively, p , 0.05) (Fig. 3D).
Although cardiac index was not different between the two
groups (2.2 6 0.6 and 2.0 6 0.6 liters/min per m2, respectively,
p 5 NS), total pulmonary resistance was significantly lower in
CPTE than in PPH (11 6 5 and 20 6 6 U, respectively, p ,
0.01). Despite these significant differences in pulmonary he-
modynamic variables, no variable was capable of separating
these two groups without significant overlap.
Illustrated in Figure 4 are comparisons of the three pro-
posed indexes for differentiating CPTE from PPH. As shown in
Figure 4 (left), PPf was significantly higher in CPTE than in
PPH (1.41 6 0.20 and 0.80 6 0.18, respectively, p , 0.001) and
separated the two groups without overlap. The cutoff value to
separate the two groups was 1.1. Figure 4 (center) illustrates
the CV of pulmonary artery pressure. The CV was significantly
higher in CPTE than in PPH (0.45 6 0.06 and 0.25 6 0.06,
respectively, p , 0.001) and was also capable of separating the
Figure 2. Representative pulmonary artery pressure tracings from a
patient with CPTE (left) and one with PPH (right). Although systolic
pressures are comparable between CPTE and PPH, pulse pressure is
much higher in CPTE than in PPH.
Figure 3. Pulmonary hemodynamic variables in CPTE
and PPH. Systolic pulmonary artery pressure was
slightly lower in CPTE than in PPH (A). Diastolic
pulmonary artery pressure was much lower in CPTE
than in PPH (B). Mean pulmonary artery pressure was
also significantly lower in CPTE than in PPH (C). Pulse
pressure was significantly higher in CPTE than in PPH
(D). Solid circles 5 individual data; open circles 5
mean values; bars 5 6 SD.
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two groups without overlap. The cutoff value to separate the
two groups was 0.35. Figure 4 (right) depicts TA1/2, which was
significantly lower in CPTE than in PPH (0.35 6 0.02 and
0.43 6 0.03, respectively, p , 0.001), and separated the two
groups reasonably well. Receiver operating characteristic curve
analysis indicated that sensitivity of TA1/2 to differentiate
CPTE from the combined group of CPTE and PPH was 0.96,
when the cutoff value was chosen as 0.385 (14). The specificity
for excluding CPTE from the combined group of CPTE and
PPH was 0.92. Thus, accentuated pulsatility relative to mean
pressure would be useful in differentiating between CPTE and
PPH. None of the three indexes (i.e., PPf, CV and TA1/2)
significantly correlated with age in the CPTE or PPH groups.
Discussion
We have showed that although conventional variables of
pulmonary artery pressure failed to differentiate between
CPTE and PPH, waveform analysis focusing on pulsatility
made this differentiation possible.
Clinical implications in differentially diagnosing CPTE and
PPH on the basis of configuration of pulmonary artery pres-
sure waveform. In clinical settings, the etiologic diagnosis of
pulmonary hypertension remains a challenge. Noninvasive
techniques, such as radioisotopic ventilation and perfusion
scanning and computed tomography, have been extremely
useful in the differential diagnosis of pulmonary hypertension.
However, these techniques can sometimes fail to make the
diagnosis, necessitating angiographic studies (15). Although
pulmonary angiography is a well established technique for
evaluating pulmonary artery disease, it can occasionally lead to
sudden cardiovascular collapse and even death (16). Thus,
there is an obvious need to develop tools to help in the
etiologic diagnosis of severe pulmonary hypertension. We
demonstrated in the present study that analysis of the pulmo-
nary artery pressure waveform configuration provides useful
information in differentiating between CPTE and PPH. Be-
cause measurement of pulmonary artery pressure by a balloon-
tipped flow-directed catheter is relatively safe compared with
pulmonary angiography, the finding that analysis of the pul-
monary artery pressure waveform configuration helped to
differentiate CPTE from PPH makes it an extremely attractive
clinical tool.
Why do CPTE and PPH have different waveforms? In
CPTE, thrombi attached to the proximal arteries narrow their
lumen size and possibly stiffen the arterial wall. Narrowing the
arteries would result in increased resistance of the proximal
arteries. Stiffening the proximal arteries would also increase
characteristic impedance of the pulmonary artery. Although
characteristic impedance reflects the dynamic mechanical
properties of the proximal arteries, the impedance behaves as
if it were viscous resistance (17). Namely, thrombi in the
proximal arteries would effectively increase proximal artery
resistance through various mechanisms. Pulmonary peripheral
resistance would not markedly increase because the peripheral
arteries are not the site of primary lesions of CPTE. Thus, the
ratio of proximal resistance to peripheral resistance would
increase markedly in CPTE. This makes systolic pressure, that
is, in-phase with arterial flow, high relative to mean pressure.
In contrast, diastolic pressure relative to mean pressure would
be low because the stiffened arteries shorten the time constant
of diastolic pressure decay. Thus, large pulse pressure relative
to mean pressure would be the characteristic waveform of
CPTE. Various investigators (10–12,18) have attributed the
widened pulse pressure to decreased arterial compliance and
increased characteristic impedance in systemic arteries.
In contrast, in PPH, the peripheral arteries were narrowed.
Thus, it is likely that peripheral arterial resistance would
preferentially increase without comparable changes in charac-
teristic impedance. These changes in mechanical properties
would increase mean arterial pressure without comparable
increases in pulse pressure. Thus, differences between the
waveforms of pulmonary artery pressure in CPTE and PPH
would be most manifest through a comparison of their pulsa-
tilities.
Indexes to quantify pulmonary artery pulsatility relative to
mean pressure. In this investigation, we used three indexes to
quantify pulsatility. PPf is the ratio of pulse pressure to mean
pressure. Suga (19) demonstrated that a pure increase in
characteristic impedance resulted in the prolongation of ejec-
tion time. This means that in CPTE, both prolongation of the
ejection time and widening of the pulse pressure would take
Figure 4. Comparison of pulsatility between
CPTE and PPH. Fractional pulse pressure (PPf)
was significantly higher in CPTE than in PPH (p ,
0.001) and separated the two groups without over-
lap (left). The average coefficient of variation (CV)
was significantly higher in CPTE than in PPH (p ,
0.001) (center) and was capable of separating the
two groups without overlap. The average fractional
time to half the pressure area (TA1/2) was signifi-
cantly lower in CPTE than in PPH (p , 0.001)
(right). Symbols as in Figure 3.
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place. Because PPf does not take into account the prolongation
of ejection time, we derived the other two indexes.
The CV of pulmonary artery pressure is defined as the ratio
of the square root of pulsatile power to the static power of
pulmonary artery pressure. Because prolongation of ejection
time will increase the dynamic power of pulmonary artery
pressure, this index is capable of quantifying both the prolon-
gation of ejection time and the widening of pulse pressure. As
we anticipated, it also separated the two groups well.
In this investigation, we used a fluid-filled pressure record-
ing system. We anticipated that the recorded pressure would
erroneously oscillate in some patients. Because both PPf and
CV would be sensitive to the oscillation, we derived TA1/2 as
an index relatively insensitive to the oscillation. It also sepa-
rated the two groups reasonably well.
Although all three indexes indeed differentiated CPTE
from PPH, we conjecture that under poor recording conditions
they might behave differently. The performance of these
indexes under such conditions remains to be investigated.
Effects of vasodilators. In this investigation, so as to avoid
possible clinical deterioration, we did not discontinue vasodi-
lators. The number of patients who received beraprost sodium
and those who received calcium channel antagonists was not
different between the CPTE and PPH groups. Thus, it is
unlikely that the vasodilators systematically biased the results
of this study.
Moreover, we separately analyzed the diagnostic signifi-
cance of pulmonary artery pulsatility in the subgroups with no
vasodilator therapy (CPTE: n 5 14; PPH: n 5 8). The results
indicated that PPf was markedly higher in CPTE than in PPH
(1.42 6 0.21 and 0.78 6 0.17, respectively, p , 0.001). The CV
also separated the two groups (0.47 6 0.07 and 0.24 6 0.05,
respectively, p , 0.001), as did TA1/2 (0.35 6 0.03 and 0.44 6
0.03, respectively, p , 0.001). These results were in line with
those obtained from the total group. Thus, vasodilator therapy
did not appear to significantly modulate the basic characteris-
tics of the pulmonary artery pressure waveform of CPTE or
PPH.
Study limitations. There are several limitations of the
present study. We retrospectively analyzed a limited number of
patients only. Obviously, the performance of the proposed
indexes, such as sensitivity and specificity in differentiating
between CPTE and PPH, depends on the patient cohort
investigated. To generalize the results of this study, prospective
studies involving many patients are essential. Nevertheless,
accentuated pulsatility relative to mean pressure in CPTE
would be expected to remain a useful, valid observation
because it is based on the fundamental mechanical character-
istics of CPTE and PPH.
Many investigators have suggested (20,21) that the patho-
physiology of CPTE and PPH may overlap to a certain extent.
We made the diagnosis of CPTE only when we could docu-
ment thrombi in the proximal arteries. Thus, it is possible that
CPTE that did not have angiographically detectable thrombi
was diagnosed as PPH. Conversely, PPH that happened to
have detectable thrombi would have been diagnosed as CPTE.
Although there exists this degree of uncertainty in diagnosis,
the proposed analysis of the pulmonary artery waveform
provided useful information consistent with angiographic find-
ings and revealed the mechanical properties of the pulmonary
arteries. These features of the proposed analysis are particu-
larly important because the correct diagnosis of CPTE is vital
for life-saving surgical procedures such as thromboendarterec-
tomy (1). Thus, we believe that the waveform analysis is useful
as a clinical tool.
We used a fluid-filled system to record pulmonary artery
pressure. If we could have used a high fidelity pressure
transducer, the recorded pressure waveform would have been
more accurate. However, this does not mean that the wave-
form analysis using the fluid-filled recording system is invalid.
The fact that we could differentiate CPTE from PPH using the
fluid-filled system should be interpreted not as a weakness but
as a strength of the study.
In this investigation, we hypothesized that characteristic
impedance would be higher in CPTE than in PPH. One can
directly measure characteristic impedance when high fidelity
instantaneous pulmonary flow and pressure are available (22–
24). Further, more elaborate studies are essential to deepen
our understanding of the mechanism that differentially modu-
lates the pulmonary artery waveform in CPTE and PPH.
Conclusions. Pulmonary artery pressure waveform analysis
can offer an additional, new approach in the differential
diagnosis of CPTE and PPH.
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